- Ophthalmic screening every three months is now strongly recommended for patients at high risk for uveitis.
- Intra-ocular or periocular GC injections are conditionally recommended against as part of therapy.
- Starting a DMARD is conditionally recommended in patients who are newly diagnosed with clinically active uveitis and require topical GC, with no time frame for waiting before systemic treatment can begin.
- Starting adalimumab is conditionally recommended as the first bDMARD over other DMARDs.
- Using an above-standard JIA dose of a TNFi is conditionally recommended when starting treatment.
- Starting methotrexate is now conditionally recommended as the first csDMARD over other csDMARDs.
Volunteers Welcome
Dr. Onel said more help for updating the guideline is always welcome. “It’s a lot of work. If people are interested, please volunteer,” she said. “It’s really necessary.”
Thomas R. Collins is a freelance medical writer based in Florida.
